BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

OncoMed Pharmaceuticals, Inc. 

800 Chesapeake Drive

Redwood City  California  94063  U.S.A.
Phone: 650-995-8200 Fax: 650-298-8600


SEARCH JOBS




Industry
Pharmaceutical

Segment
Start Up





 Company News
OncoMed Pharmaceuticals, Inc. (OMED) To Present At The 13th Annual Biotechnology Industry Organization (BIO) Investor Forum 10/7/2014 7:53:52 AM
OncoMed Pharmaceuticals, Inc. (OMED) Announces Selection Of First Small Molecule Product Candidate Targeting The Wnt Pathway Under Collaboration With Bayer Pharma AG 9/30/2014 7:57:24 AM
OncoMed Pharmaceuticals, Inc. (OMED) Presents Encouraging Data From Clinical Trials Of Tarextumab (Anti-Notch2/3) In Pancreatic Cancer And Small Cell Lung Cancer At The ESMO 2014 Congress 9/29/2014 11:12:18 AM
OncoMed Pharmaceuticals, Inc. (OMED)'s Demcizumab Phase 1b Clinical Trials Show Encouraging Safety And Anti-Tumor Activity At ESMO 9/29/2014 8:32:16 AM
OncoMed Pharmaceuticals, Inc. (OMED) To Present New And Emerging Data From Demcizumab (Anti-DLL4, OMP-21M18) And Tarextumab (Anti-Notch2/3, OMP-59R5) Clinical Studies At The European Society For Medical Oncology 2014 Congress 9/17/2014 10:30:19 AM
Redwood City's OncoMed Pharmaceuticals, Inc. (OMED) Moves Forward On Drug Trials Halted Due To Side Effects 9/4/2014 3:04:58 PM
OncoMed Pharmaceuticals, Inc. (OMED) To Present At The Morgan Stanley (MST) Global Healthcare Conference 9/2/2014 10:27:28 AM
OncoMed Pharmaceuticals, Inc. (OMED) Says FDA Lifts Partial Hold On Cancer Drug Trials For Vantictumab 8/28/2014 7:41:38 AM
OncoMed Pharmaceuticals, Inc. (OMED) Announces Second Quarter 2014 Financial Results 8/7/2014 9:00:29 AM
OncoMed Pharmaceuticals, Inc. (OMED) Initiates Randomized Phase 2 "ALPINE" Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) For Pancreatic Cancer 7/16/2014 7:27:10 AM
12345678910